

Author Index Volume 31 (2009)

- Abeler, V.M., see Pretorius, M.E. (4) 251–259
Akgül, B., see Westphal, K. (3) 213–226
Alberici, P., see Mesker, W.E. (3) 169–178
Albertson, D.G., see Kuijper, A. (1) 31–39
Amadori, D., see Calistri, D. (1) 11–17
Ambrosio, M.R., see Zatelli, M.C. (6) 457–465
Antonaci, S., see Fransvea, E. (3) 227–233
Antonacopoulou, A., see Bravou, V. (1) 41–51
Arrondini, M., see Valente, G. (6) 423–436
- Baak, J.P.A., see Janssen, E.A.M. (5) 335–343
Baak, J.P.A., see Skaland, I. (4) 261–271
Bade, L.K., see Fijneman, R.J.A. (5) 345–356
Baldewijns, M.M., I.J.H. van Vlodrop, K.M. Smits, P.B. Vermeulen, G.G. Van den Eynden, F. Schot, T. Roskams, H. van Poppel, M. van Engeland and A.P. de Bruïne, Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel–Lindau gene (5) 371–382
Barbano, R., see Savino, M. (3) 203–211
Basson, M.D., see Wang, S. (4) 273–289
Bellini, M., see Magnani, I. (5) 357–370
Bello, L., see Magnani, I. (5) 357–370
Bergner, A., see Schrödl, K. (4) 301–315
Berns, E.M.J.J., see Kuijper, A. (1) 31–39
Bloemena, E., see Graveland, A.P. (4) 317–328
Bosch, L.J.W., see Fontijn, D. (3) 179–190
Bossertoff, A.K., see Kaufmann, S. (6) 415–422
Boven, E., see Fontijn, D. (3) 179–190
Boven, E., see van Houdt, I.S. (5) 407–413
Braakhuis, B.J.M., see Graveland, A.P. (4) 317–328
Braakhuis, B.J.M., see Smeets, S.J. (4) 291–300
Brakenhoff, R.H., see Graveland, A.P. (4) 317–328
Brakenhoff, R.H., see Smeets, S.J. (4) 291–300
Bravou, V., A. Antonacopoulou, H. Papadaki, K. Floratou, M. Stavropoulos, V. Episkopou, C. Petropoulou and H. Kalofonos, TGF- β repressors SnoN and Ski are implicated in human colorectal carcinogenesis (1) 41–51
- Calistri, D., C. Rengucci, C. Molinari, E. Ricci, E. Cavargini, E. Scarpi, G.L. Milandri, C. Fabbri, A. Ravaioli, A. Russo, D. Amadori and R. Silvestrini, Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer (1) 11–17
Capparuccia, L., see Valente, G. (6) 423–436
Carella, M., see Savino, M. (3) 203–211
Castino, R., see Valente, G. (6) 423–436
Cavargini, E., see Calistri, D. (1) 11–17
Copetti, M., see Savino, M. (3) 203–211
Cormier, R.T., see Fijneman, R.J.A. (5) 345–356
Cummings, M., J. Iremonger, C.A. Green, A.M. Shaaban and V. Speirs, Gene expression of ER β isoforms in laser microdissected human breast cancers: Implications for gene expression analyses (6) 467–473

- Danielsen, H.E., see Pretorius, M.E. (4) 251–259
- Datta Gupta, S., see Sharma, G. (6) 487–500
- Davidson, B., see Pretorius, M.E. (4) 251–259
- de Bree, R., see Graveland, A.P. (4) 317–328
- de Bruïne, A.P., see Baldewijns, M.M. (5) 371–382
- de Gruijl, T.D., see van Houdt, I.S. (5) 407–413
- de Leng, W.W.J., see Sitarz, R. (6) 475–485
- de Maaker, M., see Graveland, A.P. (4) 317–328
- de Weger, R.A., see Moelans, C.B. (1) 1–10
- degli Uberti, E., see Zatelli, M.C. (6) 457–465
- Devilee, P., see Jonsdottir, A.B. (3) 191–201
- Doeleman, M., see Heideman, D.A.M. (5) 329–333
- Duyndam, M.C.A., see Fontijn, D. (3) 179–190
- Edelmann, M., see Schrödl, K. (4) 301–315
- Eerenstein, S.E.J., see Graveland, A.P. (4) 317–328
- Elshof, S., see Moelans, C.B. (1) 1–10
- Episkopou, V., see Bravou, V. (1) 41–51
- Eyfjörd, J.E., see Jonsdottir, A.B. (3) 191–201
- Ezendam, C., see Moelans, C.B. (1) 1–10
- Fabbri, C., see Calistri, D. (1) 11–17
- Fazio, V.M., see Savino, M. (3) 203–211
- Feyen, O., see Hassan, M. (6) 437–456
- Fijneman, R.J.A., L.K. Bade, J.R. Peham, M.A. van de Wiel, V.W.M. van Hinsbergh, G.A. Meijer, M.G. O’Sullivan and R.T. Cormier, Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways (5) 345–356
- Floratou, K., see Bravou, V. (1) 41–51
- Fontijn, D., L.J.W. Bosch, M.C.A. Duyndam, M.P.A. van Berkel, M.L. Janmaat and E. Boven, Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK (3) 179–190
- Fransvea, E., A. Paradiso, S. Antonaci and G. Giannelli, HCC heterogeneity: Molecular pathogenesis and clinical implications (3) 227–233
- Galamb, B., see Galamb, O. (1) 19–29
- Galamb, O., F. Sipos, S. Spisák, B. Galamb, T. Krenács, G. Valcz, Z. Tulassay and B. Molnár, Potential biomarkers of colorectal adenoma–dysplasia–carcinoma progression: mRNA expression profiling and *in situ* protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes (1) 19–29
- Gallegos-Ruiz, M.I., see Kramer, D. (3) 161–167
- Garrubba, M., see Savino, M. (3) 203–211
- Giannelli, G., see Fransvea, E. (3) 227–233
- Giercksky, K.-E., see Pretorius, M.E. (4) 251–259
- Graveland, A.P., M. de Maaker, B.J.M. Braakhuis, R. de Bree, S.E.J. Eerenstein, E. Bloemena, C.R. Lee-mans and R.H. Brakenhoff, Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients (4) 317–328
- Green, C.A., see Cummings, M. (6) 467–473
- Grinstein, E., see Hassan, M. (6) 437–456
- Grivas, P.D., V. Tzelepi, G. Sotiropoulou-Bonikou, Z. Kefalopoulou, A.G. Papavassiliou and H. Kalo-fonos, Expression of ER α , ER β and co-regulator PELP1/MNAR in colorectal cancer: Prognostic significance and clinicopathologic correlations (3) 235–247
- Gudlaugsson, E., see Janssen, E.A.M. (5) 335–343
- Gudlaugsson, E., see Skaland, I. (4) 261–271
- Hassan, M., O. Feyen and E. Grinstein, Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation (6) 437–456
- Hazrah, P., see Sharma, G. (6) 487–500

- Heideman, D.A.M., F.B. Thunnissen, M. Doeleman, D. Kramer, H.M. Verheul, E.F. Smit, P.E. Postmus, C.J.L.M. Meijer, G.A. Meijer and P.J.F. Snijders, A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes (5) 329–333
- Heideman, D.A.M., see Kramer, D. (3) 161–167
- Hooijberg, E., see van Houdt, I.S. (5) 407–413
- Huber, R.M., see Schrödl, K. (4) 301–315
- Hui Ru Guo, L., see Skaland, I. (4) 261–271
- Iremonger, J., see Cummings, M. (6) 467–473
- Isidoro, C., see Valente, G. (6) 423–436
- Janmaat, M.L., see Fontijn, D. (3) 179–190
- Janssen, E.A.M., I.T. Øvestad, I. Skaland, H. Sjøiland, E. Gudlaugsson, K.H. Kjelleevold, A. Nysted, J.-A. Søreide and J.P.A. Baak, LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer (5) 335–343
- Janssen, E.A.M., see Skaland, I. (4) 261–271
- Jonsdottir, A.B., M.P.G. Vreeswijk, R. Wolterbeek, P. Devilee, H.J. Tanke, J.E. Eyfjörd and K. Szuhai, *BRCA2* heterozygosity delays cytokinesis in primary human fibroblasts (3) 191–201
- Jungeburt, J.M.C., see Mesker, W.E. (3) 169–178
- Kalofonos, H., see Bravou, V. (1) 41–51
- Kalofonos, H., see Grivas, P.D. (3) 235–247
- Kaufmann, S., S. Kuphal, T. Schubert and A.K. Bosserhoff, Functional implication of Netrin expression in malignant melanoma (6) 415–422
- Kefalopoulou, Z., see Grivas, P.D. (3) 235–247
- Kerim, S., see Valente, G. (6) 423–436
- Kjelleevold, K.H., see Janssen, E.A.M. (5) 335–343
- Kramer, D., F.B. Thunnissen, M.I. Gallegos-Ruiz, E.F. Smit, P.E. Postmus, C.J.L.M. Meijer, P.J.F. Snijders and D.A.M. Heideman, A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations (3) 161–167
- Kramer, D., see Heideman, D.A.M. (5) 329–333
- Krenács, T., see Galamb, O. (1) 19–29
- Kuennen-Boumeester, V., see Kuijper, A. (1) 31–39
- Kuijper, A., A.M. Snijders, E.M.J.J. Berns, V. Kuennen-Boumeester, E. van der Wall, D.G. Albertson and P.J. van Diest, Genomic profiling by array comparative genomic hybridization reveals novel DNA copy number changes in breast phyllodes tumours (1) 31–39
- Kuphal, S., see Kaufmann, S. (6) 415–422
- Kuppen, P.J.K., see Mesker, W.E. (3) 169–178
- Larizza, L., see Magnani, I. (5) 357–370
- Leemans, C.R., see Graveland, A.P. (4) 317–328
- Leemans, C.R., see Smeets, S.J. (4) 291–300
- Leguit, R.J., see Sitarz, R. (6) 475–485
- Liefers, G.-J., see Mesker, W.E. (3) 169–178
- Liu, L., R. Xie, C. Yang and W.L. McKeehan, Dual function microtubule- and mitochondria-associated proteins mediate mitotic cell death (5) 393–405
- Lothe, R.A., see Pretorius, M.E. (4) 251–259
- Maciejewski, R., see Sitarz, R. (6) 475–485
- Magnani, I., C. Novielli, M. Bellini, G. Roversi, L. Bello and L. Larizza, Multiple localization of endogenous MARK4L protein in human glioma (5) 357–370
- Mannello, F., G.A. Tonti and V. Medda, Protein oxidation in breast microenvironment: Nipple aspirate fluid collected from breast cancer women contains increased protein carbonyl concentration (5) 383–392
- McKeehan, W.L., see Liu, L. (5) 393–405
- Medda, V., see Mannello, F. (5) 383–392

- Meijer, C.J.L.M., see Heideman, D.A.M. (5) 329–333
- Meijer, C.J.L.M., see Kramer, D. (3) 161–167
- Meijer, C.J.L.M., see van Houdt, I.S. (5) 407–413
- Meijer, G.A., see Fijneman, R.J.A. (5) 345–356
- Meijer, G.A., see Heideman, D.A.M. (5) 329–333
- Mesker, W.E., G.-J. Liefers, J.M.C. Junggeburst, G.W. van Pelt, P. Alberici, P.J.K. Kuppen, N.F. Miranda, K.A.M. van Leeuwen, H. Morreau, K. Szuhai, R.A.E.M. Tollenaar and H.J. Tanke, Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I–II colon cancer patients (3) 169–178
- Milandri, G.L., see Calistri, D. (1) 11–17
- Milne, A.N., see Sitarz, R. (6) 475–485
- Minoia, M., see Zatelli, M.C. (6) 457–465
- Miranda, N.F., see Mesker, W.E. (3) 169–178
- Mirza, S., see Sharma, G. (6) 487–500
- Moelans, C.B., R.A. de Weger, M.T.M. van Blokland, C. Ezendam, S. Elshof, M.G.J. Tilanus and P.J. van Diest, HER-2/*neu* amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and *in situ* hybridization (1) 1–10
- Moesbergen, L.M., see van Houdt, I.S. (5) 407–413
- Molè, D., see Zatelli, M.C. (6) 457–465
- Molinari, C., see Calistri, D. (1) 11–17
- Molnár, B., see Galamb, O. (1) 19–29
- Morreau, H., see Mesker, W.E. (3) 169–178
- Morsink, F.H.M., see Sitarz, R. (6) 475–485
- Murgo, R., see Savino, M. (3) 203–211
- Nicotra, G., see Valente, G. (6) 423–436
- Nindl, I., see Westphal, K. (3) 213–226
- Novielli, C., see Magnani, I. (5) 357–370
- Nysted, A., see Janssen, E.A.M. (5) 335–343
- Oelmez, H., see Schrödl, K. (4) 301–315
- Offerhaus, G.J.A., see Sitarz, R. (6) 475–485
- O’Sullivan, M.G., see Fijneman, R.J.A. (5) 345–356
- Oudejans, J.J., see van Houdt, I.S. (5) 407–413
- Øvestad, I.T., see Janssen, E.A.M. (5) 335–343
- Papadaki, H., see Bravou, V. (1) 41–51
- Papavassiliou, A.G., see Grivas, P.D. (3) 235–247
- Paradiso, A., see Fransvea, E. (3) 227–233
- Parrella, P., see Savino, M. (3) 203–211
- Parshad, R., see Sharma, G. (6) 487–500
- Peham, J.R., see Fijneman, R.J.A. (5) 345–356
- Petropoulou, C., see Bravou, V. (1) 41–51
- Polkowski, W.P., see Sitarz, R. (6) 475–485
- Postmus, P.E., see Heideman, D.A.M. (5) 329–333
- Postmus, P.E., see Kramer, D. (3) 161–167
- Prat, M., see Valente, G. (6) 423–436
- Pretorius, M.E., H. Wæhre, V.M. Abeler, B. Davidson, L. Vlatkovic, R.A. Lothe, K.-E. Giercksky and H.E. Danielsen, Large scale genomic instability as an additive prognostic marker in early prostate cancer (4) 251–259
- Ralhan, R., see Sharma, G. (6) 487–500
- Ravaioli, A., see Calistri, D. (1) 11–17
- Rengucci, C., see Calistri, D. (1) 11–17
- Ricci, E., see Calistri, D. (1) 11–17
- Roskams, T., see Baldewijns, M.M. (5) 371–382

- Roversi, G., see Magnani, I. (5) 357–370
- Russo, A., see Calistri, D. (1) 11–17
- Santini, S.A., see Savino, M. (3) 203–211
- Savino, M., P. Parrella, M. Copetti, R. Barbano, R. Murgo, V.M. Fazio, V.M. Valori, M. Carella, M. Garrubba and S.A. Santini, Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients (3) 203–211
- Scarpi, E., see Calistri, D. (1) 11–17
- Schot, F., see Baldewijns, M.M. (5) 371–382
- Schrödl, K., H. Oelmez, M. Edelmann, R.M. Huber and A. Bergner, Altered Ca²⁺-homeostasis of cisplatin-treated and low level resistant non-small-cell and small-cell lung cancer cells (4) 301–315
- Schubert, T., see Kaufmann, S. (6) 415–422
- Shaaban, A.M., see Cummings, M. (6) 467–473
- Sharma, G., S. Mirza, Y.-H. Yang, R. Parshad, P. Hazrah, S. Datta Gupta and R. Ralhan, Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients (6) 487–500
- Silvestrini, R., see Calistri, D. (1) 11–17
- Sipos, F., see Galamb, O. (1) 19–29
- Sitarz, R., R.J. Leguit, W.W.J. de Leng, F.H.M. Morsink, W.P. Polkowski, R. Maciejewski, G.J.A. Offerhaus and A.N. Milne, Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines (6) 475–485
- Skaland, I., E.A.M. Janssen, E. Gudlaugsson, L. Hui Ru Guo and J.P.A. Baak, The prognostic value of the proliferation marker Phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer (4) 261–271
- Skaland, I., see Janssen, E.A.M. (5) 335–343
- Sluijter, B.J.R., see van Houdt, I.S. (5) 407–413
- Smeets, S.J., R.H. Brakenhoff, B. Ylstra, W.N. van Wieringen, M.A. van de Wiel, C.R. Leemans and B.J.M. Braakhuis, Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis (4) 291–300
- Smit, E.F., see Heideman, D.A.M. (5) 329–333
- Smit, E.F., see Kramer, D. (3) 161–167
- Smits, K.M., see Baldewijns, M.M. (5) 371–382
- Snijders, A.M., see Kuijper, A. (1) 31–39
- Snijders, P.J.F., see Heideman, D.A.M. (5) 329–333
- Snijders, P.J.F., see Kramer, D. (3) 161–167
- Søiland, H., see Janssen, E.A.M. (5) 335–343
- Søreide, J.-A., see Janssen, E.A.M. (5) 335–343
- Sotiropoulou-Bonikou, G., see Grivas, P.D. (3) 235–247
- Speirs, V., see Cummings, M. (6) 467–473
- Spisák, S., see Galamb, O. (1) 19–29
- Stavropoulos, M., see Bravou, V. (1) 41–51
- Storey, A., see Westphal, K. (3) 213–226
- Szuhai, K., see Jonsdottir, A.B. (3) 191–201
- Szuhai, K., see Mesker, W.E. (3) 169–178
- Tagliati, F., see Zatelli, M.C. (6) 457–465
- Tamagnone, L., see Valente, G. (6) 423–436
- Tanke, H.J., see Jonsdottir, A.B. (3) 191–201
- Tanke, H.J., see Mesker, W.E. (3) 169–178
- Thunnissen, F.B., see Heideman, D.A.M. (5) 329–333
- Thunnissen, F.B., see Kramer, D. (3) 161–167
- Tilanus, M.G.J., see Moelans, C.B. (1) 1–10
- Tollenaar, R.A.E.M., see Mesker, W.E. (3) 169–178
- Tonti, G.A., see Mannello, F. (5) 383–392
- Tulassay, Z., see Galamb, O. (1) 19–29
- Tzelepi, V., see Grivas, P.D. (3) 235–247

- Valcz, G., see Galamb, O. (1) 19–29
- Valente, G., G. Nicotra, M. Arrondini, R. Castino, L. Capparuccia, M. Prat, S. Kerim, L. Tamagnone and C. Isidoro, Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression (6) 423–436
- Valori, V.M., see Savino, M. (3) 203–211
- van Berkel, M.P.A., see Fontijn, D. (3) 179–190
- van Blokland, M.T.M., see Moelans, C.B. (1) 1–10
- van de Wiel, M.A., see Fijneman, R.J.A. (5) 345–356
- van de Wiel, M.A., see Smeets, S.J. (4) 291–300
- Van den Eynden, G.G., see Baldewijns, M.M. (5) 371–382
- van der Wall, E., see Kuijper, A. (1) 31–39
- van Diest, P.J., see Kuijper, A. (1) 31–39
- van Diest, P.J., see Moelans, C.B. (1) 1–10
- van Engeland, M., see Baldewijns, M.M. (5) 371–382
- van Hinsbergh, V.W.M., see Fijneman, R.J.A. (5) 345–356
- van Houdt, I.S., B.J.R. Sluijter, P.A.M. van Leeuwen, L.M. Moesbergen, E. Hooijberg, C.J.L.M. Meijer, T.D. de Gruijl, J.J. Oudejans and E. Boven, Absence of Granzyme B positive tumour-infiltrating lymphocytes in primary melanoma excisional biopsies is strongly associated with the presence of sentinel lymph node metastasis (5) 407–413
- van Leeuwen, K.A.M., see Mesker, W.E. (3) 169–178
- van Leeuwen, P.A.M., see van Houdt, I.S. (5) 407–413
- van Pelt, G.W., see Mesker, W.E. (3) 169–178
- van Poppel, H., see Baldewijns, M.M. (5) 371–382
- van Vlodrop, I.J.H., see Baldewijns, M.M. (5) 371–382
- van Wieringen, W.N., see Smeets, S.J. (4) 291–300
- Verheul, H.M., see Heideman, D.A.M. (5) 329–333
- Vermeulen, P.B., see Baldewijns, M.M. (5) 371–382
- Vlatkovic, L., see Pretorius, M.E. (4) 251–259
- Vreeswijk, M.P.G., see Jonsdottir, A.B. (3) 191–201
- Wæhre, H., see Pretorius, M.E. (4) 251–259
- Wang, S. and M.D. Basson, Integrin-linked kinase: A multi-functional regulator modulating extracellular pressure-stimulated cancer cell adhesion through focal adhesion kinase and AKT (4) 273–289
- Westphal, K., B. Akgül, A. Storey and I. Nindl, Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures (3) 213–226
- Wolterbeek, R., see Jonsdottir, A.B. (3) 191–201
- Xie, R., see Liu, L. (5) 393–405
- Yang, C., see Liu, L. (5) 393–405
- Yang, Y.-H., see Sharma, G. (6) 487–500
- Ylstra, B., see Smeets, S.J. (4) 291–300
- Zatelli, M.C., D. Molè, F. Tagliati, M. Minoia, M.R. Ambrosio and E. degli Uberti, Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF- κ B (6) 457–465